Humacyte clinical trials and publications.


L. E. Niklason, J. H. Lawson

“Bioengineered Human Blood Vessels”
Science 370, eaaw8682 (2020). 
DOI: 10.11.20/science.aaw8682


2019: “Clinical Outcomes of Arteriovenous Access in Incident Hemodialysis patients with Medicare Coverage 2012-2014”



2019: “Cost Attributable to Arteriovenous Fistulae and Arteriovenous Graft Placements in Hemodialysis patients with Medicare Coverage”


Science Translational Medicine​

Bioengineered human acellular vessels recellularize and evolve into living blood vessels after human implantation.

March 27, 2019



2017: “Arteriovenous fistulae for Hemodialysis: A Systematic Review and Meta-Anaylsis of Efficacy and Safety Outcomes”


The Lancet

Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials

May 14, 2016

Science Translational Medicine​

Readily Available Tissue-Engineered Vascular Grafts

February 2, 2011

Vascular Repair V005

A Phase 2 Study for the Evaluation of Safety and Efficacy of Humacyte’s Human Acellular Vessel for Vascular Replacement or Reconstruction in Patients with Life or Limb-threatening Vascular Trauma


Clinical Trial for AV Access


Human Acellular Vessel – A Controlled Comparison
of Efficacy and Safety Study

Human Acellular Vessel vs. Arteriovenous Fistula
for Hemodialysis Access

Phase II Clinical Trial for Peripheral Arterial Disease

Scroll to Top